Prospective randomized study on sexual health and self-perceived quality of life (PROMs) in patients treated for cervical cancer
Key facts
- Where
- Barcelona, Madrid, Pamplona és Valencia, SpanyolországSee the 7 sites
- Phase
- 4. fázis
Where in Spanyolország
- Hospital Clinic de BarcelonaBarcelona, SpanyolországTaking people
- Hospital Vall d'HebronBarcelona, SpanyolországTaking people
- Hospital Clínico San CarlosMadrid, SpanyolországTaking people
- Hospital La PazMadrid, SpanyolországTaking people
- Hospital Universitario 12 de OctubreMadrid, SpanyolországTaking people
- Hospital Universitario de NavarraPamplona, SpanyolországTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
- Trial code
- EU 2025-521460-36-00
- Record updated
- 2026. augusztus 20.
- Original description
To assess the improvement in sexual function and self-perceived quality of life using PROMs (Patient-Reported Outcomes) in patients treated for cervical cancer who undergo a multimodal intervention in the sexual sphere and lifestyle compared to those who undergo care within routine clinical practice.Read full original descriptionShow less
To assess the improvement in sexual function and self-perceived quality of life using PROMs (Patient-Reported Outcomes) in patients treated for cervical cancer who undergo a multimodal intervention in the sexual sphere and lifestyle compared to those who undergo care within routine clinical practice.
Inclusion: Women of legal age; Patients with primary cervical cancer stage FIGO I-III (initial or locally advanced) of squamous histology, adenocarcinoma or adenosquamous; Patients treated for cancer with surgery and/or radiotherapy ± systemic treatment in the Gynaecological Oncology Units of hospitals in Spain; Complete response after oncospecific treatment was obtained; Signature of the informed consent (IC) by the patient or responsible family member; Patients who have been sexually active within the last 12 month.
Exclusion: Patients under 18 years of age; Pregnancy or breastfeeding; Partial response after completion of oncospecific treatment; Patients with premalignant pathology; Diagnosis of a tumor of non-cervical origin or atypical histologies; Impossibility of completing the questionnaires included in the protocol autonomously; Contraindications to the use of vaginal estrogens; Patients undergoing fertility-sparing treatment (trachelectomy or conization); Patients undergoing palliative treatment.